April 25, 2024 19:00 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Lok Sabha Elections 2024: ECI issues notices to BJP, Congress on complaints against Modi, Rahul | Massive landslide hits Arunachal Pradesh, a large section of Highway-33 washed away | Actress Tamannaah Bhatia summoned by Maharashtra cyber cell in 2023 illegal IPL streaming case | Bihar CM Nitish Kumar's party leader shot dead in Patna | Centre moves Supreme Court seeking modification of 2012 verdict in 2G spectrum case
Alzheimer's drug hailed as breakthrough Alzheimer
Pixabay

Alzheimer's drug hailed as breakthrough

India Blooms News Service | @indiablooms | 30 Nov 2022, 02:10 pm

London: The first drug to slow the destruction of the brain in Alzheimer's has been heralded as momentous.

The research breakthrough ends decades of failure and shows a new era of drugs to treat Alzheimer's -- the most common form of dementia -- is possible, BBC reported.

Yet the medicine, lecanemab, has only a small effect and its impact on people's daily lives is debated.

And the drug works in the early stages of the disease, so most would miss out without a revolution in spotting it, the BBC said.

Lecanemab attacks the sticky gunge -- called beta amyloid -- that builds up in the brains of people with Alzheimer's.

For a medical field littered with duds, despair and disappointment, some see these trial results as a triumphant turning point.

Alzheimer's Research UK said the findings were "momentous".

One of the world's leading researchers behind the whole idea of targeting amyloid 30 years ago, Prof John Hardy, said it was "historic" and was optimistic "we're seeing the beginning of Alzheimer's therapies", the BBC reported.

Prof Tara Spires-Jones, from the University of Edinburgh, said the results were "a big deal because we've had a 100 per cent failure rate for a long time".

Currently, people with Alzheimer's are given other drugs to help manage their symptoms, but none change the course of the disease.

(With UNI inputs)

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.